|Articles|December 14, 2022
Understanding the true cost of transparency reporting
Author(s)PwC
When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, new systems were quickly — and possibly haphazardly — put in place to handle snowballing transparency reporting requirements. Now the cracks are beginning to show, and PLS companies are realizing the true cost of transparency reporting.
Trending on PharmExec
1
M&A Roundup: Johnson & Johnson Collaborates with Sail Biomedicines, Processa Pharmaceuticals Acquires Vidya Therapeutics, Relation Collaborates with GSK
2
Replimune Shares Crash Following FDA Review of Melanoma Treatment
3
Addressing Launch Drift to Optimize Product Launches
4
When Foreign Investments in Pharma and Biotech Become a National Security Concern
5